These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


365 related items for PubMed ID: 17965124

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis.
    Rojas-Villarraga A, Diaz FJ, Calvo-Páramo E, Salazar JC, Iglesias-Gamarra A, Mantilla RD, Anaya JM.
    J Autoimmun; 2009 Feb; 32(1):64-9. PubMed ID: 19117726
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL.
    Arthritis Rheum; 2001 Sep; 44(9):2009-17. PubMed ID: 11592361
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility.
    van der Helm-van Mil AH, Huizinga TW, Schreuder GM, Breedveld FC, de Vries RR, Toes RE.
    Arthritis Rheum; 2005 Sep; 52(9):2637-44. PubMed ID: 16142711
    [Abstract] [Full Text] [Related]

  • 8. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK, Sheen DH, Lee YJ, Mun YR, Park M, Shim SC.
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [Abstract] [Full Text] [Related]

  • 9. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
    Carrier N, Cossette P, Daniel C, de Brum-Fernandes A, Liang P, Ménard HA, Boire G.
    Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation.
    Escalante A, Haas RW, del Rincón I.
    Arch Intern Med; 2005 Jul 25; 165(14):1624-9. PubMed ID: 16043681
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M.
    Mikrobiyol Bul; 2008 Oct 25; 42(4):669-74. PubMed ID: 19149089
    [Abstract] [Full Text] [Related]

  • 17. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis.
    Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE.
    Arthritis Rheum; 2004 Nov 25; 50(11):3450-7. PubMed ID: 15529378
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels.
    Bos WH, Ursum J, de Vries N, Bartelds GM, Wolbink GJ, Nurmohamed MT, van der Horst-Bruinsma IE, van de Stadt RJ, Crusius JB, Tak PP, Dijkmans BA, van Schaardenburg D.
    Ann Rheum Dis; 2008 Sep 25; 67(9):1347-50. PubMed ID: 18388157
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 19.